Biophilia Tracker may treat depression

The aim of the study was to evaluate if Biophilia Tracker can offer quantifiable results in patients with recurrent major depressive disorder and with mild, moderate, or severe depressive episodes by decreasing the level of depression due to the application of bioresonance therapy as independently or complementary treatment. 

The study included 140 patients suffering from depression, divided into three groups. The first group (40 patients) received solely Biophilia Tracker  therapy, the second group (40 patients) received pharmacological treatment with antidepressants combined with Biophilia Tracker therapy, and the third group (60 patients) received solely pharmacological treatment with antidepressants. 

The assessment of depression was made using the H-amilton Depression Rating Scale, with 17 items, at the beginning of the Biophilia Tracker treatment and the end of the five weeks of treatment, aiming to decrease the level of depression. The study identified the existence of a statistically significant difference for the treatment methods applied to the analyzed groups (p=0.0001), and we found that the therapy accelerates the healing process in patients with depressive disorders. Improvement was observed for the analyzed groups, with a decrease of the mean values between the initial and final phase of the level of depression, of delta for H-amilton score of 3.1, 3.8 and 2.3, respectively.

 We concluded that the Biophilia Tracker therapy could be useful in the treatment of recurrent major depressive disorder with moderate depressive episodes independently or as a complementary therapy to antidepressants.